跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 160 条关于
“Cereblon (CRBN)”
全部
160
临床试验
48
药物
61
机构
2
资讯
49
10个月前
Kangpu's Novel Cereblon Modulator Shows 50% Response Rate in Heavily Pre-treated Multiple Myeloma Patients
去年
ADAR1 Gene Identified as Key Driver of Lenalidomide Resistance in Multiple Myeloma
上个月
The Second Act of Thalidomide: From Teratogen to the Foundation of Targeted Protein Degradation
去年
Kangpu's Novel Molecular Glue Modulator KPG-818 Receives IND Approval in China for Multiple Myeloma Treatment
去年
Monte Rosa's AI-Powered Discovery Engine Expands Molecular Glue Degrader Target Space in Science Publication
2年前
BeiGene's BGB-16673 Shows Promise in Blood Cancer Treatment with Projected $9M Revenue by 2037
3个月前
Molecular Glue Degraders of HuR Suppress BRAF-Mutant Colorectal Cancer
9个月前
CRBN Gene Mutations Show Variable Impact on Myeloma Drug Response, Enabling Precision Treatment Selection
去年
PROTAC Technology Emerges as Next-Generation Approach for IDO1-Targeted Cancer Immunotherapy
去年
Targeted Protein Degradation Emerges as Multi-Billion Dollar Therapeutic Frontier with First PROTAC Approval Expected in 2026
第 1 页,共 5 页
上一页
下一页